🧬 Reading the DNA of This Pharma Play

It's Readers Choice time... ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Note: Is edwardlorilla1986.paxforex@blogger.com your correct email? You haven't clicked in a while and we're concerned you might lose access. Please confirm your address with one click here. Stock of the Week: Reading the DNA of This Pharma Play SPONSORED Andy's most elite invitation yet... Andy Snyder just revealed Manward's BIGGEST undertaking to date... It's called The Alternative Wealth Summit. In it, he's revealing a new class of investments that is completely outside the volatile stock and cryptocurrency markets. Already, this new investment has shown top gains of... 11,264%... 13,991%... 32,309%... 41,936%... All in one year! And it's just getting started... Click here for the urgent details. Alpesh Patel Trading Champion It's Readers Choice time here at Stock of the Week... Reader E.L. asked for my thoughts on a big-name pharma company that's been on quite a ride over the past couple of years. [Alexander Green Is Going ALL-IN! Discover Where He's Investing $100K+ Right Now.] It's growing earnings at a huge 76% per year... and its CROCI (cash return on capital invested) is very strong at 25%. Very nice. But there are a few red flags investors need to be aware of. You may be surprised by my analysis of this one... Get all the details - including the ticker - in my latest Stock of the Week video. Click here or on the image below to watch it. REVEAL THE STOCK Happy hunting, Alpesh P.S. Have a stock you'd like me to look at? Send the ticker to mailbag@manwardpress.com, and I'll be sure to cover it in a future video. SPONSORED Market Millionaire Discovers "Perfect Stock" He bought Amazon when it was trading around $30... Netflix when it was around $2... And Apple when it was less than $1 a share... And now... Market millionaire Alexander Green says he's discovered the "Perfect Stock" that could be the key to your retirement. Find out about this $4 stock before share prices go up.   Want more content like this? YES NO   Alpesh Patel | Trading Champion Alpesh Patel is an award-winning hedge fund and private equity fund manager, international bestselling author, and entrepreneur. He is the founder and CEO of Praefinium Partners, a Financial Times top FTSE 100 forecaster, and a senior Dealmaker in the U.K.'s Department for International Trade. As a recognized authority on fintech, online trading and venture capital, his past and current client list includes American Express, Merrill Lynch HSBC, Charles Schwab, Goldman Sachs, Barclays... and more.   Was this email forwarded to you? Click here to sign up! You are receiving this email because you subscribed to Manward Financial Digest. To unsubscribe from Manward Financial Digest, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press, LLC | Attn: Support Team | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.682.5210 | International: +1.443.353.4263 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Manward Financial Digest. © 2023 Manward Press, LLC | All Rights Reserved Nothing published by Manward Press should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Manward Press should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.